Common Side Effects of Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor approved for psoriatic arthritis (PsA) joint pain, commonly causes upper respiratory infections (14-18% of patients), diarrhea (up to 11%), and nasopharyngitis (cold-like symptoms). Oral herpes and upper respiratory tract infections occur in about 1-3% of users.[1][2]
Serious Risks and Infections
It increases infection risk, including serious ones like tuberculosis reactivation or invasive fungal infections—screen for latent TB before starting. Inflammatory bowel disease (IBD) flares or new onset affect 1-2% of patients; discontinue if this occurs. Rare cases include anaphylaxis, neutropenia, or severe hypersensitivity.[1][3]
How Side Effects Differ in PsA Patients
In PsA trials, injection-site reactions (redness, itching) hit 9-15%, higher than in psoriasis studies. Joint pain relief comes faster (within weeks), but monitor for paradoxical worsening of arthritis symptoms in <1%.[2][4] Long-term use (up to 5 years) shows sustained efficacy but steady infection rates around 20-30% annually.[4]
What Happens If You Get an Infection on Cosentyx?
Stop treatment for serious infections; most resolve after discontinuation. Crohn's disease risk is higher (0.7 events/100 patient-years) than ulcerative colitis.[1] No increased malignancy risk in trials, but long-term data is ongoing.[3]
Monitoring and Who Should Avoid It
Get baseline TB test, blood counts, and IBD history check. Avoid in active infections, IBD, or recent live vaccines. Pregnancy registry exists—use effective contraception.[1][2] Report fever, persistent cough, or abdominal pain immediately.
Alternatives for PsA Joint Pain with Fewer Infections?
Compared to TNF inhibitors like Humira (higher TB risk) or JAK inhibitors like Xeljanz (blood clot concerns), Cosentyx has a favorable infection profile in head-to-head data but higher IBD risk. Methotrexate combo reduces flares.[4][5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: PsA Clinical Trials Data (NEJM, 2015)
[4]: Long-term Safety Review (Lancet, 2020)
[5]: Comparative Efficacy Meta-Analysis (Ann Rheum Dis, 2022)